Pittsburgh Law Office of Alfred G. Yates Jr., P.C. Files Class Action Lawsuit On Behalf of Shareholders of Provectus Biopharmaceuticals, Inc. (PVCT) and Announces Investigations into Aegerion Pharmaceuticals (AEGR), Aeroflex Holding (ARX), Annie's (BNNY),

PITTSBURGH, June 16, 2014 /PRNewswire/ -- Notice is hereby given the Law Office of Alfred G. Yates Jr., P.C. has filed a class action in the United States District Court for the Middle District of Tennessee on behalf of purchasers of Provectus Biopharmaceuticals, Inc. ("Provectus") (NYSE: PVCT) publicly traded securities during the period between December 17, 2013 and May 22, 2014 (the "Class Period").

The complaint alleges that throughout the Class Period, defendants violated the federal securities laws by disseminating false and misleading statements to the investing public regarding the prospects for PV-10. 

The firm is also investigating actions on behalf of investors for the following companies: Aegerion Pharmaceuticals, Inc. (AEGR), Aeroflex Holding Corp. (NYSE: ARX), Annie's, Inc. (NYSE: BNNY), Altisource Residential Corporation (NYSE: RESI), Fusion-io, Inc. (NYSE: FIO), Hertz Global Holdings, Inc. (NYSE: HTZ), Hittite Microwave Corp. (Nasdaq: HITT), Medifast Inc. (NYSE: MED), PetroLogistics LP (NYSE: PDH), Ply Gem Holdings, Inc. (NYSE: PGEM), Protective Life Corp. (NYSE: PL), Regional Management Corp. (NYSE: RM), Ruby Tuesday, Inc. (NYSE: RT), tw telecom, Inc. (Nasdaq: TWTC), and World Wrestling Entertainment Inc. (NYSE: WWE).

If you are an investor in any of the above companies and wish learn more about any of the investigations or have any questions, please contact Alfred G. Yates Jr., Esquire at 1-800-391-5164, toll free.  You may also contact him by email at [email protected] or through the law office web site at http://yatesclassactionlaw.com/contact_us.php.

SOURCE Law Office of Alfred G. Yates Jr., P.C.

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.